NCT03662516View on ClinicalTrials.gov

A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

January 19, 2019

Study Completion Date

January 19, 2019

Conditions
Healthy Females
Interventions
DRUG

PF-04965842

Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.

DRUG

Ethinyl estradiol (EE) and levonorgestrel (LN)

Single dose of Oral tablet containing 30 ug EE and 150 ug of LN

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03662516 - A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects | Biotech Hunter | Biotech Hunter